Institutions

1 Immune-mediated Inflammatory Skin Disease research group, IMIBIC/Reina Sofía University Hospital/University of Córdoba, Menendez Pidal Ave, 14004 Córdoba, Spain.
2 Department of Dermatology, Reina Sofía University Hospital, Menendez Pidal Ave, 14004 Córdoba, Spain.
3 Agencia de Evaluación de Tecnologías Sanitarias (AETSA), Consejería de Salud, Junta de Andalucía, 41020 Sevilla, Spain.
4 Department of Pharmacy, Reina Sofía University Hospital, Menendez Pidal Ave, 14004 Córdoba, Spain.

Correspondence

Juan Ruano
Department of Dermatology
Reina Sofía University Hospital
Menendez Pidal Ave, 14004 Córdoba, Spain
e-mail: juanruanoruiz@mac.com
ORCID Id: 0000-0002-0286-4107

Conflict of interest

FG-G has received honoraria for research from Pfizer, and for lecturing from AbbVie, Janssen-Cilag and Novartis; JR has received honoraria for lecturing and grants for research from Pfizer, honoraria for lecturing from Janssen-Cilag and Novartis, and other financial benefits from AbbVie and Novartis. MA-L, JR, FG-G, JG-M, and BI-T are members of the Cochrane Bias Methods Group and Skin Group. JLS-C, PA-M, BM-L, PJC-F, and MG-P have no disclosures.

Funding sources

This work was supported, in part, by project ICI1400136 to JR, integrated into the National Plan of R+D+I 2008-2011 and co-financed by the ISCIII-Subdirección General de Evaluación and European Regional Development Fund (ERDF), by project PIN-0316-2017 of the Consejería de Salud, Junta de Andalucía (Spain) to JR, and by grant PP13/009 of Plan Propio de movilidad para investigadores del Instituto Maimonides de Investigacion Biomédica de Córdoba (IMIBIC). No funding was received from any pharmaceutical company.